The Perivascular Fat Attenuation Index Improves the Diagnostic Performance for Functional Coronary Stenosis

Hankun Yan, Na Zhao, Wenlei Geng, Zhihui Hou, Yang Gao *,† and Bin Lu *,†

Department of Radiology, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China; yanhankun2022@163.com or yanhankun@fuwaihospital.org (H.Y.); 15810686235@163.com (N.Z.); sd785291190@gmail.com (W.G.); konglingyihui@126.com (Z.H.)
*Correspondence: gaoyang226@126.com (Y.G.); blu@vip.sina.com or lvbin@fuwaihospital.org (B.L.);
†These authors contributed equally to this work.

Abstract: Background: Coronary computed tomography angiography (CCTA) is an established first-line test in the investigation of patients with suspected coronary artery disease (CAD), while the perivascular fat attenuation index (FAI) derived from CT seems to be a feasible and efficient tool for the identification of ischemia. The association between the FAI and lesion-specific ischemia as assessed by fractional flow reserve (FFR) remains unclear. Methods: In a total of 261 patients, 294 vessels were assessed for CCTA stenosis, vessel-specific FAI, lesion-specific FAI, and plaque characteristics. The diagnostic accuracies of each parameter and the combined approach were analyzed via the receiver operating characteristic curve (ROC) with FFR as the reference standard. The determinants of FAI were statistically analyzed. Results: The cutoff values of vessel-specific FAI and lesion-specific FAI scores calculated according to the Youden index were −70.97 and −73.95 HU, respectively. No significant differences were noted between them; however, they exhibited a strong correlation. No significant differences were noted between the area under the curve (AUC) scores of vessel-specific FAI (0.677), lesion-specific FAI (0.665), and CCTA (0.607) (p > 0.05 for all) results. The addition of two FAI measures to the CCTA showed improvements in the discrimination (AUC) and reclassification ability (relative integrated discrimination improvement (IDI) and category-free net reclassification index (NRI)), vessel-specific FAI (AUC, 0.696; NRI, 49.6%; IDI, 5.9%), and CCTA (0.607) (p > 0.05 for all) results. The addition of two FAI measures to the CCTA showed improvements in the discrimination (AUC) and reclassification ability (relative integrated discrimination improvement (IDI) and category-free net reclassification index (NRI)), vessel-specific FAI (AUC, 0.696; NRI, 49.6%; IDI, 5.9%), and lesion-specific FAI scores (AUC, 0.676; NRI, 43.3%; IDI, 5.4%); (p < 0.01 for all). Multivariate analysis revealed that low-attenuation plaque (LAP) volume was an independent predictor of two FAI measures. Conclusion: The combined approach of adding vessel-specific FAI or lesion-specific FAI scores could improve the identification of ischemia compared with CCTA alone. The LAP volume was the independent risk factor for both tools.

Keywords: coronary artery disease; coronary computed tomography angiography; ischemia; fat attenuation index

1. Introduction

Coronary artery disease (CAD) remains the leading cause of death in upper-middle and high-income economies [1]. Coronary computed tomography angiography (CCTA) is an established first-line test in the investigation of patients with suspected CAD, because it has a high negative predictive value and high accuracy in the diagnosis and exclusion of CAD [2–4]. However, only about half of obstructive coronary stenosis cases lead to ischemia [5,6] and are associated with worsened survival [7]. Therefore, it is important to find other factors beyond coronary stenosis to improve the recognition of lesion-specific ischemia.

The perivascular adipose tissue (PVAT) interacts with the arterial wall in a bidirectional manner and has been associated with the process of atherogenesis characterized by calcification and adverse clinical prognosis [8], which implies that there might be a...
common inflammatory background between PVAT and calcification. The perivascular fat attenuation index (FAI) is a metric derived from CT that captures the balance between lipids and water within PVAT. The FAI is associated with an increased risk of all-cause and cardiac mortality and adverse clinical outcomes [9], and could also help in detecting the presence of culprit lesions in patients with acute myocardial infarction [10,11]. Higher lesion-specific FAI and vessel-specific FAI values are linked to hemodynamically significant stenosis [12–15]. However, studies on the relationship between lesion-specific FAI and vessel-specific FAI are still inadequate. This study hypothesizes that there is a high degree of consistency between lesion-specific FAI and vessel-specific FAI, and that both of them can improve the diagnostic performance of CCTA in identifying lesion-specific ischemia. Accordingly, this study aims to investigate the relationship between lesion-specific FAI and vessel-specific FAI, as well as the associations between them and with coronary stenosis severity and ischemia using fractional flow reserve (FFR) as a reference standard.

2. Materials and Methods

2.1. Study Population

In this study, we retrospectively collected data from patients with suspected or known stable CAD from January 2012 to March 2020 at our institution. The inclusion criteria were as follows: (1) patients with angina or angina-equivalent symptoms; (2) the presence of at least one lesion with stenosis diameters ranging between 30% and 90% of the major epicardial vessels (diameter \( \geq 2 \) mm) based on CCTA; (3) patients who underwent CCTA, invasive coronary angiography (ICA), and FFR measurements within 2 weeks. The exclusion criteria were as follows: (1) age < 18 years; (2) previous history of myocardial infarction; (3) previous history of coronary revascularization; (4) insufficient quality of CCTA images; (5) patients with anatomic variations in the heart or coronary arteries. This study was approved by the Institutional Review Board of our institution, and informed consent from all patients in this study was waived.

2.2. Coronary Computed Tomography Angiography Acquisition

All CCTA scans were performed using a dual-source CT scanner (Definition Flash, Siemens Healthineers, Forchheim, Germany). All patients were scanned by prospective electrocardiogram (ECG) gating technology, and images were acquired at 35–75% of the R–R interval. Beta-blockers were administered when the heart rate > 75 beats/min. Sublingual glyceryl trinitrate was administered before scanning in all patients. The scanning parameters were shown as follows: tube voltage, 100 kV or 120 kV (according to the body mass index of patients); tube current, automatic tube current modulation; rotation time, 0.28 s per rotation; slice thickness, 0.75 mm; gap, 0.70 mm. The optimal cardiac phase was selected by radiology technicians. During scanning, 60–70 mL of contrast medium (Iohexol, Shuangbei 350; Beilu Pharmaceutical Co., Ltd., Beijing, China) was injected into the antecubital vein through a dual-cylinder high-pressure syringe (Stellant; Medrad, Indiaola, PA, USA) at a speed of 4.5–5.0 mL/s and then flushed with 30–40 mL of saline at the same speed. The calcification score (CS) of the coronary artery was measured as previously described by Agatston [16]. Stenosis severity was categorized as 30–49%, 50–69%, and 70–90% in coronary segments \( \geq 2 \) mm by two experienced local radiologists who were blinded to the patient’s condition. When there were different opinions, a consensus was drawn after discussion. Coronary stenosis \( \geq 50% \) was considered as obstructive stenosis.

2.3. Coronary Plaque Analysis

Plaque areas > 1 mm\(^2\) in coronary segments \( \geq 2 \) mm were measured with a semi-automated dedicated plaque analysis software (Coronary Plaque Analysis, version 2.0, Siemens Healthineers, Forchheim, Germany). The quantitative plaque components were automatically generated according to scan-specific thresholds within the manually designated area. Adjustments were performed if necessary. The remodeling index, plaque length, total plaque volume (TPV), low-attenuation plaque (LAP), intermediate-attenuation...
plaque (IAP), and calcified plaque (CP) values were previously measured. The remodeling index is the ratio of the largest vessel diameter at the lesion site to the vessel diameter at the proximal reference point, while a remodeling index > 1.1 indicates positive remodeling (PR) [17]. Two experienced observers performed the analyses and the average values were used for further analysis.

2.4. Perivascular Fat Attenuation Index Acquisition

Coronary PVAT around the epicardial coronary arteries with an attenuation window of −190 to −30 Hounsfield units (HU), is defined as the adipose tissue located within a distance from the outer vessel wall equal to the diameter of the adjacent coronary vessel [10]. Perivascular FAI was defined as the mean CT attenuation of PVAT, and it was also performed by a semi-automated post-processing software (Coronary Plaque Analysis, version 2.0, Siemens Healthineers, Forchheim, Germany). Vessel-specific FAI values were acquired as described previously. To avoid the effects of the aortic wall, the most proximal 10 mm of the right coronary artery (RCA) was excluded and the proximal 10–50 mm of the vessel was analyzed [9]. In the left anterior descending artery (LAD) and left circumflex artery (LCX), the proximal 40 mm of each vessel was analyzed. Lesion-specific FAI scores for lesion plaques interrogated with FFR evaluation were measured from the proximal to the distal shoulder of the lesion. Additional manual optimization was performed, if necessary, to avoid the effects of non-adipose tissues, such as the small side branches or coronary veins. The time periods required for vessel-specific FAI and lesion-specific FAI analyses are between 6 and 8 min and between 3 and 5 min, respectively. Vessel-specific FAI and lesion-specific FAI scores of 30 consecutive vessels were measured by two experienced radiologists who were blinded to clinical, CCTA, and FFR data to evaluate the reproducibility between observers.

2.5. Invasive Coronary Angiography and Fractional Flow Reserve Measurements

Invasive FFR measurements were assessed during the ICA inspection, and all operations were performed by a cardiovascular physician with extensive work experience. ICA and FFR were performed according to standard practices, as previously described [18]. FFR was the ratio of the pressure of the distal coronary artery to the aortic pressure during the maximum hyperemia, and it was measured by using a 0.014 inch pressure guidewire (St Jude Medical Systems, Minneapolis, MN, USA). The FFR was measured at approximately 2 cm distal to the lesion stenosis. A hyperemic state was induced by continuous administration of intravenous adenosine at a rate of 160 mg/kg/min. Invasive FFR ≤ 0.80 was considered that the stenosis was physiologically significant and causal of lesion-specific ischemia [19,20].

2.6. Statistical Analysis

Continuous variables were presented as means ± standard deviation (SD) in the case of normal distribution and medians (interquartile range) in the case of non-normal distribution, while categorical variables were expressed as numbers and percentages. To evaluate interobserver reproducibility, intraclass correlation coefficients were used to evaluate the interobserver variability of vessel-specific FAI and lesion-specific FAI scores. The receiver operator characteristic curve (ROC) was created to predict the area under the curve (AUC), while p-value, diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) scores were calculated with a 95% confidence interval (CI), using invasive FFR as the reference standard. The AUCs of different methods were compared using the method previously described by Delong et al. [21]. The accuracy, sensitivity, and specificity of different methods were compared using Cochran’s Q test, then the post-Dunn test and Bonferroni correction were used for intergroup comparison [22], and PPV and NPV were compared using a chi-square test. Additive values of vessel-specific FAI and lesion-specific FAI measures were evaluated by relative integrated discrimination improvement (IDI) and category-free net reclassification index (NRI) scores [23,24]. The
best cutoff values of vessel-specific FAI and lesion-specific FAI scores were selected according to the Youden index (defined as sensitivity + specificity − 1). Data were compared using Student’s t-test, Mann–Whitney U test, Kruskal–Wallis test, or chi-square test as appropriate. Univariable and multivariable logistic regression analyses were performed to determine predictive factors of vessel-specific FAI and lesion-specific FAI, respectively. All statistical analyses were performed with SPSS 25.0 (IBM Corp., Armonk, NY, USA), MedCalc 19.0.4 (MedCalc Software, Ostend, Belgium), and R 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria) software. Statistical tests were two-tailed, and p-values < 0.05 indicated statistical significance.

3. Results

3.1. Clinical Characteristics

The flowchart of patient selection is shown in Figure 1. Finally, a total of 261 patients were included in this study, in whom 294 vessels were interrogated by invasive FFR, including LAD (210; 71.4%), LCX (35; 11.9%), and RCA (49; 16.7%), respectively. The baseline characteristics of the patients are shown in Table 1. The mean age of the patients was 56.3 ± 8.7 years, and men accounted for 72.0% (188) of patients in this study. Lesion-specific ischemia was found in 45.2% (133/294) of vessels in 44.1% (115/261) of patients by obtaining FFR as a reference; the mean FFR value was 0.80 ± 0.11. There were 206 (70.8%) vessels with obstructive stenosis based on CCTA results.

![Figure 1. Flowchart of patient’s selection. CCTA, coronary computed tomography angiography; FFR, fractional flow reserve.](image-url)
Table 1. Baseline characteristics of patients.

| Characteristic                        | Value |
|---------------------------------------|-------|
| Number of patients, n                 | 261   |
| Number of lesion vessels, n           | 294   |
| Age, year                             | 56.3 ± 8.7 |
| Male, n (%)                           | 188 (72.03) |
| Body mass index, kg/m²                | 25.9 ± 3.1 |
| Risk factors                          |       |
| Hypertension, n (%)                   | 153 (58.6) |
| Diabete, n (%)                        | 83 (31.8) |
| Dyslipidemia, n (%)                   | 222 (85.1) |
| Smoker, n (%)                         | 140 (53.6) |
| Family history of CAD, n (%)          | 47 (18.0) |
| Distribution of lesion                |       |
| LAD, n (%)                            | 210 (71.4) |
| LCX, n (%)                            | 35 (11.9) |
| RCA, n (%)                            | 49 (16.7) |
| Calcification score                   | 63.00 (3.18–208.45) |
| <400, n (%)                           | 136 (52.1) |
| ≥400, n (%)                           | 125 (47.9) |
| CCTA stenosis                         |       |
| Stenosis between 30–49%, n (%)       | 64 (21.77) |
| Stenosis between 50–69%, n (%)       | 114 (38.78) |
| Stenosis between 70–90%, n (%)       | 119 (40.48) |
| Invasive FFR                          | 0.80 ± 0.11 |
| Vessels with FFR ≤ 0.80, n (%)        | 133 (45.2) |
| RCA with FFR ≤ 0.80, n (%)           | 12 (4.1) |
| LAD with FFR ≤ 0.80, n (%)           | 46 (15.6) |
| LCX with FFR ≤ 0.80, n (%)           | 75 (25.5) |

Note: Continuous variables are expressed as means ± standard deviation values or median (interquartile range) values, and categorical variables are expressed as numbers (percentages) of patients or lesions. CAD, coronary artery disease; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; CCTA, coronary computed tomography angiography; FFR, fractional flow reserve.

3.2. Discrimination of Ischemia

The intraclass correlation coefficients were shown as follows: vessel-specific FAI, 0.98 (95% CI, 0.95–0.99); lesion-specific FAI, 0.91 (95% CI, 0.62–0.97). The distribution of vessel-specific FAI and lesion-specific FAI scores is shown in Figure 2. There were no significant differences between vessel-specific FAI and lesion-specific FAI scores (p = 0.135), and they demonstrated a strong, almost collinear association (R = 0.770, p < 0.001).

Per-vessel AUCs for CCTA, vessel-specific FAI, and lesion-specific FAI scores were 0.607 (95% CI, 0.549–0.663), 0.677 (95% CI, 0.620–0.730), and 0.665 (95% CI, 0.608–0.719), respectively (Figure 3). According to the Youden index, the optimal cutoff values for vessel-specific FAI and lesion-specific FAI scores were –70.97 HU and –73.95 HU, respectively. Table 2 provides measures of diagnostic characteristics. Although the AUC of the vessel-specific FAI was higher than other methods, there were no statistically significant differences between them; the difference in AUC for the lesion-specific FAI was 0.012 (95% CI, −0.033–0.057, p = 0.612), and for the CCTA was 0.070 (95% CI, −0.004–0.143, p = 0.062). The difference in AUC of the lesion-specific FAI was 0.058 (95% CI, −0.015–0.131, p = 0.118) higher than CCTA, but there was still no statistically significant difference between them. No statistically significant differences in accuracy between CCTA, vessel-specific FAI, or lesion-specific FAI (all p > 0.05) were noted. The sensitivity of the CCTA and lesion-specific FAI methods were both higher than that of the vessel-specific FAI (p = 0.001, p = 0.011, respectively), while there were no statistically significant differences between CCTA and lesion-specific FAI (p = 1.000). The specificity of the vessel-specific FAI was higher than that of CCTA and lesion-specific FAI (p = 0.002, p = 0.013, respectively), and the difference between the CCTA and lesion-specific FAI was not statistically significant (p = 1.000). There were no statistically significant differences in NPV and PPV among them (p = 0.825, p = 0.356, respectively). A representative case is given in Figure 4.
Figure 2. Comparisons of vessel-specific FAI and lesion-specific FAI scores: (A) the distribution of vessel-specific FAI and lesion-specific FAI scores, with medians, quartiles, and ranges shown in the box plot; (B) the correlation between vessel-specific FAI and lesion-specific FAI scores, with the scatter diagram showing a positive correlation between them ($R = 0.770, p < 0.001$). FAI, fat attenuation index; HU, Hounsfield unit; NS, non-statistical significance.

Figure 3. Receiver operating characteristic curves for the CCTA, vessel-specific FAI, and lesion-specific FAI in predicting ischemia: (A) ROC curves for predicting ischemia using CCTA, vessel-specific FAI, and lesion-specific FAI. (B) ROC curves of models using CCTA with and without vessel-specific FAI and lesion-specific FAI, respectively. Cutoff values of $-70.97$ HU for vessel-specific FAI and $-73.95$ HU for lesion-specific FAI according to the Youden index were used for the comparison between CCTA with and without these scores. CCTA, coronary computed tomography angiography; FAI, fat attenuation index; ROC, receiver operating characteristic curves; HU, Hounsfield unit.
Table 2. Per-vessel diagnostic accuracy levels of CCTA, vessel-specific FAI, and lesion-specific FAI.

|                | True Positive * | True Negative * | False Positive * | False Negative * | % Accuracy | % Sensitivity | % Specificity | % PPV | % NPV | AUC  |
|----------------|-----------------|-----------------|-------------------|------------------|------------|---------------|---------------|-------|-------|------|
| CCTA           | 121             | 49              | 112               | 12               | 57.82      | 90.98         | 30.44         | 51.93 | 80.33 | 0.607|
|                | (54.71−60.83)   | (84.77−95.25)   | (23.44−38.17)     | (49.05−54.80)    |            |               |               |       |       |      |
| Vessel-specific FAI > −70.97 HU | 104             | 75              | 86                | 29               | 60.88      | 78.20         | 46.58         | 54.74 | 72.12 | 0.677|
|                | (0.578−0.639)   | (70.21−84.89)   | (38.70−54.60)     | (50.50−58.90)    |            |               |               |       |       |      |
| Lesion-specific FAI > −73.95 HU | 118             | 53              | 108               | 15               | 58.16      | 88.72         | 32.92         | 52.21 | 77.94 | 0.665|
|                | (55.12−61.22)   | (82.08−93.55)   | (25.73−40.75)     | (49.11−55.29)    |            |               |               |       |       |      |

Note: Except otherwise indicated, data are percentages with 95% confidence intervals. * Data are raw data. CCTA, coronary computed tomography angiography; FAI, fat attenuation index; PPV, positive predictive value; NPV, negative predictive value; AUC, area under curve.

Figure 4. Example of a 42-year-old man with chest pain: (A) CCTA image showed a lesion analyzed with dedicated plaque analysis software proximal to the LAD with stenosis ranging between 70 and 90% (white arrow); (B,C) color-coded CPR image reveals that the mean perivascular FAIs of the lesion (lesion-specific FAI) and proximal 40 mm of LAD (vessel-specific FAI) were −63.75 HU and −67.92 HU, respectively; (D) measurement list shows the contents of various plaque components; (E) ICA showed that the stenosis degree of the lesion was about 90% (red arrow), and then FFR confirmed that the stenosis was hemodynamically significant (FFR = 0.75). CCTA, coronary computed tomography angiography; FAI, fat attenuation index; PPV, positive predictive value; NPV, negative predictive value; AUC, area under curve.
3.3. Additive Values of FAI to CCTA

Figure 3 presents the ROCs for the three models, while the AUC, category-free NRI, and relative IDI values for the three models are shown in Table 3. Compared with the model using only CCTA, both diagnostic models using CCTA with vessel-specific FAI or lesion-specific FAI demonstrated higher AUC (CCTA along, 0.607, 95% CI, 0.549–0.663; CCTA + vessel-specific FAI, 0.696, 95% CI, 0.640–0.748, p < 0.001; CCTA + lesion-specific FAI, 0.676, 95% CI, 0.619–0.729, p < 0.001). Additionally, both the vessel-specific FAI and lesion-specific FAI enabled the effective reclassification of CCTA diameter stenosis results as follows: CCTA + vessel-specific FAI (NRI, 49.6%, 95% CI, 28.1–70.4%, p < 0.001; relative IDI, 5.9%, 95% CI, 3.3–8.4%, p < 0.001), CCTA + lesion-specific FAI (NRI, 43.3%, 95% CI, 25.2–61.4%, p < 0.001; relative IDI, 5.4%, 95% CI, 2.9–7.8%, p < 0.001).

Table 3. Comparison of different models for the identification of ischemia (FFR ≤ 0.80).

| Model                          | AUC (95% CI) | Difference with | p   | NRI (95% CI) | p   | IDI (95% CI) | p   |
|-------------------------------|-------------|----------------|-----|-------------|-----|-------------|-----|
| CCTA                          | 0.607 (0.549–0.663) | -              | -   | -           | -   | -           | -   |
| CCTA + Vessel-specific FAI    | 0.696 (0.640–0.748) | 0.089 (0.050–0.127) | <0.001 | 49.6% (28.1–70.4%) | <0.001 | 5.9% (3.3–8.4%) | <0.001 |
| CCTA + Lesion-specific FAI    | 0.676 (0.619–0.729) | 0.069 (0.036–0.102) | <0.001 | 43.3% (25.2–61.4%) | <0.001 | 5.4% (2.9–7.8%) | <0.001 |

Note: Data are calculated with 95% confidence intervals. FFR, fractional flow reserve; AUC, area under the curve; CI, confidence interval; NRI, net reclassification index; IDI, integrated discrimination improvement; CCTA, coronary computed tomography angiography; FAI, fat attenuation index.

3.4. Relationship between Vessel-Specific FAI, Lesion-Specific FAI, and Coronary Stenosis

The relationship between anatomical stenosis results determined by CT, vessel-specific FAI, and lesion-specific FAI is shown in Figure 5. Among the 233 vessels with obstructive stenosis (≥50%), vessel-specific FAI ≥ −70.97 HU accounted for 67.4% (157/233), while lesion-specific FAI ≤ −73.95 HU accounted for 79.8% (186/233). Among 119 severe stenosis (70–89%) lesions in CCTA, 75 (63.0%) demonstrated hemodynamic significance (invasive FFR ≤ 0.8), while moderate stenosis (50–69%) and mild stenosis (30–49%) accounted for 40.4% (46/114) and 19.7% (12/61), respectively.

3.5. Predictors of Vessel-Specific FAI and Lesion-Specific FAI

As shown in Table 4, male patients tend to have higher vessel-specific FAI and lesion-specific FAI values (p = 0.024, p = 0.001, respectively). Smoking patients also tend to have higher lesion-specific FAI values (p = 0.127). Patients with lesion-specific FAI ≥ −70.97 HU tend to have higher TPV, LAP volume, and plaque length values (p = 0.012, p = 0.002, and p = 0.010, respectively), while patients with lesion-specific FAI ≥ −73.95 HU just tend to have higher LAP volume values (p = 0.002). The results of the logistic regression are shown in Table 5. In the univariable analysis, men (OR, 1.832, 95% CI, 1.085–3.095, p = 0.024), TPV (OR, 1.002, 95% CI, 1.001–1.004, p = 0.009), LAP volume (OR, 1.009, 95% CI, 1.004–1.014, p = 0.001), and plaque length (OR, 1.018, 95% CI, 1.001–1.036, p = 0.034) were related to vessel-specific FAI scores. Additionally, men (OR, 2.708, 95% CI, 1.530–4.796, p = 0.001), smoker (OR, 1.821, 95% CI, 1.053–3.151, p = 0.032), and LAP volume (OR, 1.010, 95% CI, 1.003–1.016, p = 0.003) were related to lesion-specific FAI scores. In multivariable analysis, after adjustment, LAP volume was an independent risk factor for both vessel-specific FAI (OR, 1.008, 95% CI, 1.001–1.014, p = 0.016) and lesion-specific FAI scores (OR, 1.008, 95% CI, 1.001–1.014, p = 0.002). The relationships between the vessel-specific FAI, lesion-specific FAI, and LAP volume are shown in Figure 6, and both the differences in vessel-specific FAI and lesion-specific FAI between different LAP groups were statistically significant (p = 0.001, p < 0.001, respectively). Both the vessel-specific FAI (R = 0.201, p = 0.001) and lesion-specific FAI (R = 0.241, p < 0.001) scores were weakly correlated with LAP volume.
Figure 5. Relationship between vessel-specific FAI, lesion-specific FAI, and stenosis based on CCTA: (A,B) distribution of vessel-specific FAI (A) and lesion-specific FAI (B) scores in each group with 30–49%, 50–69%, and 70–90% diameter stenosis on CCTA. Medians, quartiles, and ranges of vessel-specific FAI and lesion-specific FAI scores are shown in the box plot. Cutoff values of vessel-specific FAI and lesion-specific FAI scores are displayed as dashed lines. FAI, fat attenuation index; CCTA, coronary computed tomography angiography.

Table 4. Patient and plaque characteristics according to vessel-specific FAI and lesion-specific FAI scores.

|                      | Vessel-Specific FAI |                  | Lesion-Specific FAI |                  |
|----------------------|---------------------|------------------|---------------------|------------------|
|                      | ≥ −70.97 HU (n = 190) | < −70.97 HU (n = 104) | p | ≥ −73.95 HU (n = 233) | < −73.95 HU (n = 68) | p |
| Age, year            | 56.4 ± 8.8          | 56.2 ± 8.6       | 0.822               | 55.9 ± 8.8       | 57.9 ± 8.3       | 0.997 |
| Male, n (%)         | 146 (76.84)         | 67 (64.42)       | 0.023               | 178 (78.76)      | 35 (58.88)       | <0.001 |
| Body mass index, kg/m² | 25.86 ± 3.15      | 25.90 ± 3.02     | 0.911               | 25.86 ± 3.15     | 25.90 ± 2.96     | 0.920 |
| hsCRP, mg/L          | 1.10 (1.57)         | 1.08 (1.74)      | 0.980               | 1.04 (1.57)      | 1.10 (1.75)      | 0.871 |
| Hypertension, n (%)  | 113 (59.47)         | 60 (64.42)       | 0.767               | 133 (58.85)      | 40 (58.82)       | 0.997 |
| Diabete, n (%)       | 56 (29.47)          | 34 (32.69)       | 0.567               | 66 (29.20)       | 24 (35.29)       | 0.339 |
| Dyslipidemia, n (%)  | 160 (84.21)         | 89 (85.58)       | 0.756               | 193 (85.40)      | 56 (82.35)       | 0.541 |
| Smoker, n (%)        | 109 (57.37)         | 50 (48.08)       | 0.126               | 130 (57.52)      | 29 (42.65)       | 0.031 |
| Family history of CAD, n (%) | 36 (18.95) | 17 (16.35) | 0.579 | 41 (18.14) | 12 (17.65) | 0.926 |
| TPV, mm³             | 282.21 (215.82)     | 231.95 (218.76)  | 0.012               | 267.21 (216.64)  | 252.89 (234.30)  | 0.182 |
| CP volume, mm³       | 17.38 (53.67)       | 15.89 (37.15)    | 0.963               | 15.53 (49.13)    | 18.41 (45.85)    | 0.308 |
| IAP volume, mm³      | 182.83 (135.15)     | 168.87 (157.20)  | 0.112               | 182.32 (132.45)  | 173.34 (168.22)  | 0.442 |
| LAP volume, mm³      | 49.70 (89.30)       | 30.65 (35.59)    | 0.002               | 44.63 (77.36)    | 28.60 (36.02)    | 0.002 |
| CS                   | 57.00 (212.35)      | 64.50 (154.15)   | 0.782               | 57.00 (188.58)   | 82.00 (314.40)   | 0.125 |
| Plaque length, mm    | 24.28 (18.98)       | 18.71 (18.52)    | 0.010               | 23.59 (18.16)    | 18.29 (23.88)    | 0.054 |
| PR, n (%)            | 57 (30.00)          | 30 (28.85)       | 0.836               | 70 (30.97)       | 17 (25.00)       | 0.344 |

Note: Unless otherwise indicated, data are means ± SD or medians (interquartile range). * Data are numbers (percentage). FAI, fat attenuation index; HU, Hounsfield unit; hsCRP, high-sensitivity C-reactive protein; CAD, coronary artery disease; TPV, total plaque volume; CP, calcified plaque; IAP, intermediate-attenuation plaque; LAP, low-attenuation plaque; CS, calcification score; PR, positive remodeling.
Table 5. Univariable and multivariable analysis for vessel-specific FAI and lesion-specific FAI.

|                              | Vessel-Specific FAI | Lesion-Specific FAI |
|------------------------------|---------------------|--------------------|
|                              | OR (95% CI)         | p                  | OR (95% CI)         | p                  |
| Age                          | 1.003 (0.976–1.031) | 0.821              | 0.973 (0.943–1.005) | 0.097              |
| Sex                          | 1.832 (1.085–3.095) | 0.024              | 2.708 (1.530–4.796) | 0.001              |
| Body mass index              | 0.996 (0.922–1.076) | 0.911              | 0.995 (0.912–1.087) | 0.919              |
| hsCRP                        | 1.025 (0.937–1.122) | 0.586              | 1.067 (0.951–1.198) | 0.267              |
| Hypertension                 | 1.076 (0.663–1.748) | 0.767              | 1.001 (0.577–1.737) | 0.997              |
| Diabete                      | 0.860 (0.514–1.440) | 0.567              | 0.756 (0.426–1.343) | 0.340              |
| Dyslipidemia                 | 0.899 (0.459–1.760) | 0.756              | 1.253 (0.607–2.587) | 0.541              |
| LAP volume                   | 1.009 (1.002–1.014) | 0.001              | 1.010 (1.003–1.016) | 0.003              |
| Smoker                       | 1.453 (0.899–2.349) | 0.127              | 1.821 (1.053–3.151) | 0.032              |
| Family history of CAD        | 1.196 (0.635–2.255) | 0.579              | 1.034 (0.509–2.102) | 0.926              |
| CP volume                    | 1.002 (1.001–1.004) | 0.009              | 1.001 (1.000–1.003) | 0.111              |
| IAP volume                   | 1.007 (1.000–1.004) | 0.034              | 1.011 (0.999–1.001) | 0.137              |
| LAP volume                   | 1.002 (0.997–1.006) | 0.405              | 0.999 (0.995–1.000) | 0.789              |
| CS                           | 1.000 (1.000–1.001) | 0.548              | 0.999 (0.999–1.000) | 0.137              |
| Plaque length                | 1.018 (1.001–1.036) | 0.034              | 1.011 (0.992–1.029) | 0.258              |
| PR                           | 1.057 (0.625–1.788) | 0.836              | 1.346 (0.726–2.495) | 0.345              |

Multivariable Analysis

|                              | Vessel-Specific FAI | Lesion-Specific FAI |
|------------------------------|---------------------|--------------------|
|                              | OR (95% CI)         | p                  | OR (95% CI)         | p                  |
| Sex                          | 1.541 (0.897–2.650) | 0.117              | 1.478 (0.780–2.800) | 0.231              |
| Smoker                       | -                   | -                  | 1.104 (0.616–1.980) | 0.729              |
| TPV                          | 1.000 (0.997–1.002) | 0.818              | -                   | -                  |
| LAP volume                   | 1.008 (1.001–1.014) | 0.016              | 1.008 (1.003–1.014) | 0.002              |
| Plaque length                | 1.010 (0.989–1.032) | 0.338              | -                   | -                  |

OR, odds ratio; CI, confidence interval; FAI, fat attenuation index; hsCRP, high-sensitivity C-reactive protein; CAD, coronary artery disease; TPV, total plaque volume; CP, calcified plaque; IAP, intermediate-attenuation plaque; LAP, low-attenuation plaque; CS, calcification score; PR, positive remodeling.

Figure 6. Distribution of vessel-specific FAI (A) and lesion-specific FAI (B) scores according to quartile of LAP volume (Q1–Q4). Values shown are medians (interquartile range). FAI, fat attenuation index; HU, Hounsfield unit; LAP, low-attenuation plaque.

4. Discussion

The main findings of this study are as follows. No significant differences were noted between vessel-specific FAI and lesion-specific FAI scores, and there was a strong, almost
collinear association between them. Secondly, the diagnostic AUCs and accuracy levels of vessel-specific FAI and lesion-specific FAI were not higher than for CCTA. However, the discrimination and reclassification ability for ischemia were significantly improved when vessel-specific FAI and lesion-specific FAI assessments, respectively, were added to CCTA. Lastly, the LAP volume was an independent risk factor for vessel-specific FAI and lesion-specific FAI values after adjusting for confounding factors.

Similar to previous studies [5,6], only 51.9% (121/233) of vessels with obstructive stenosis were hemodynamically significant in this study. Previous studies have also reported that lesion-specific ischemia diagnosed by FFR is associated with future adverse prognosis and that revascularization guided by FFR can improve event-free survival [19,20]. Consequently, this indicates that in addition to stenosis by CCTA, other non-invasive methods are needed to assist in improving the ability to discriminate ischemia.

Atherosclerosis is an inflammatory process [25] and inflammation is a key factor, not only for atherosclerotic development, but also for the progression of atherosclerotic plaques [26]. Perivascular FAI is a metric derived from CT, which reflects the presence of pericoronal inflammation [10]. The paracrine inflammatory signals from the inflamed vessel walls would prevent lipid accumulation by affecting biological processes such as adipocyte differentiation, proliferation, and lipolysis [9], thereby resulting in a shift from a lower to a higher water/lipid ratio, while the attenuation on CT images increases. Therefore, FAI would be higher when vascular inflammation occurs. Vascular inflammation is a chief contributor to endothelial dysfunction, leading to local “functional stenosis” [27,28]. FAI alone is a weak predictor of lesion-specific ischemia, because the diagnostic performance of the vessel-specific FAI or the lesion-specific FAI was not significantly higher than that of CCTA in this study. Compared to CCTA, the vessel-specific FAI or lesion-specific FAI aid in the identification of ischemia, resulting in relatively high-sensitivity and low specificity, rather than higher diagnostic AUC or accuracy. However, the discrimination and reclassification ability of hemodynamic significance stenosis were significantly improved when vessel-specific FAI and lesion-specific FAI assessments were added to CCTA, respectively, as reported previously [12–15]. Nevertheless, there were still some different results from previous studies, which may have been due to the different populations and software programs employed [29].

The measurement methods used for FAI in previous studies [12–15,29] were not consistent, which adds confusion in assessing the impacts of measurement methods on the diagnostic performance of the FAI. This study observed for the first time that there were no significant differences between vessel-specific FAI and lesion-specific FAI scores, and that there was a strong, almost collinear association between them. No significant difference in diagnostic performance was noted between the two. Therefore, the results of this study suggest that both FAI measurement methods could be applied to clinical practice. The vessel-specific FAI seems to be a more convenient and appropriate method than lesion-specific FAI because the former was measured automatically using software and it could reduce human error, meaning it had higher reliability. However, a large sample study is still needed for verification.

Patients with vessel-specific FAI scores ≥ −70.97 HU and lesion-specific FAI scores ≥ −73.95 HU tend to have higher LAP volumes. After adjustment, the LAP volume was shown to be an independent risk factor for vessel-specific FAI and lesion-specific FAI scores, and we also found that the LAP volume was positively correlated with both of these methods. Similar to our findings, Goeller et al. [30] demonstrated an increase in the burden of LAP marked by a significant increase in PVAT attenuation (p = 0.04), and there was an association between LAP burden and increased PVAT attenuation (R = 0.24, p = 0.01). LAP was the alternative to the presence of the necrotic core. The necrotic core causes inflammation and oxidative stress by improving the levels of vasoconstrictors and by reducing the production and bioavailability of vasodilators [28,31]. Moreover, vascular inflammation is associated with the FAI. Thus, the presence of necrotic cores is associated with the FAI, and this study supports these findings. In addition, CS is considered to be
a specific marker of atherosclerotic burden, which might have a common inflammatory background with PVAT. A recent study speculated that there might be a potential correlation between PVAT and CS [32]. However, the results of this study found that there was no relationship between the FAI and CS, which may be related to the patient population and drug treatment received in this study.

This study still had some limitations. First, this study was a retrospective post hoc analysis of existing data. Thus, there may be potential selection bias in this study. Second, other CT-based techniques of functional assessment such as fractional flow reserve derived from computed tomography (FFR[CT]) have been widely introduced and used. Intraindividual comparisons need to be performed in the future to determine the best single or combination approach. Finally, this study lacks clinical outcome data, and further clinical outcome studies are still needed to analyze the effectiveness of these methods.

5. Conclusions

The FAI is an additional tool used to identify patients with relevant stenosis, and the combined use of a vessel-specific FAI or lesion-specific FAI and CCTA could improve the diagnostic performance of ischemia compared with CCTA alone. Thus, the need for further invasive treatment can be better assessed in patients. The LAP volume is the independent risk factor used for both tools.

Author Contributions: Conceptualization, H.Y., Z.H., Y.G. and B.L.; methodology, H.Y., N.Z. and W.G.; software, H.Y.; validation, H.Y., N.Z. and W.G.; formal analysis, H.Y.; resources, Y.G. and B.L.; writing—original draft preparation, H.Y.; writing—review and editing, Y.G. and B.L. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Beijing Municipal Commission of Science and Technology (Z201100005620013), Clinical and Translational Medicine Research Foundation of Chinese Academy of Medical Sciences (2019XK320065), and the Ministry of Science and Technology of China, National Key Research and Development Project (2016YFC1300402).

Institutional Review Board Statement: The study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the ethics committee of Fu Wai Hospital (number: NO.2018-1076).

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors appreciate the research teams in our hospital for their work on the study.

Conflicts of Interest: All authors have no conflict of interest.

References
1. WHO. Disease Burden and Mortality Estimates; WHO: Geneva, Switzerland, 2018.
2. Moss, A.J.; Williams, M.C.; Newby, D.E.; Nicol, E.D. The Updated NICE Guidelines: Cardiac CT as the First-Line Test for Coronary Artery Disease. Curr. Cardiovasc. Imaging Rep. 2017, 10, 15. [CrossRef] [PubMed]
3. Meijboom, W.B.; Meijs, M.F.; Schuijf, J.; Cramer, M.J.; Mollet, N.R.; van Mieghem, C.A.; Nieman, K.; van Werkhoven, J.M.; Pundziute, G.; Weustink, A.C.; et al. Diagnostic Accuracy of 64-Slice Computed Tomography Coronary Angiography: A Prospective, Multicenter, Multivendor Study. J. Am. Coll. Cardiol. 2008, 52, 2135–2144. [CrossRef] [PubMed]
4. Budoff, M.J.; Dowe, D.; Jollis, J.G.; Gitter, M.; Sutherland, J.; Halamert, E.; Scherer, M.; Bellinger, R.; Martin, A.; Benton, R.; et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: Results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Un-dergoing Invasive Coronary Angiography) trial. J. Am. Coll. Cardiol. 2008, 52, 1724–1732. [PubMed]
5. Meijboom, W.B.; Van Mieghem, C.A.G.; van Pelt, N.; Weustink, A.; Pugliese, F.; Mollet, N.R.; Boersma, E.; Regar, E.; van Geuns, R.J.; de Jaegere, P.J.; et al. Comprehensive assessment of coronary artery stenoses: Computed tomography coronary angiography versus conventional coronary angiography and correlation with fractional flow reserve in patients with stable angina. J. Am. Coll. Cardiol. 2008, 52, 636–643. [CrossRef] [PubMed]
6. Shaw, L.J.; Berman, D.S.; Maron, D.J.; Mancini, G.B.J.; Hayes, S.W.; Hartigan, P.M.; Weintraub, W.S.; O'Rourke, R.A.; Dada, M.; Spertus, J.A.; et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggres-sive Drug Evaluation (COURAGE) trial nuclear substudy. *Circulation* **2008**, *117*, 1283–1291. [CrossRef] [PubMed]

7. Erne, P.; Schoenenberger, A.W.; Burchhardt, D.; Zuber, M.; Kiowski, W.; Buser, P.T.; Dubach, P.; Resnik, T.J.; Pfisterer, M. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: The SWISSII II randomized controlled trial. *JAMA* **2007**, *297*, 1985–1991. [CrossRef] [PubMed]

8. Margaritis, M.; Sanna, F.; Lazaros, G.; Akoumianakis, I.; Sheena, P.; Antonopoulos, A.S.; Duke, C.; Herdman, L.; Psarros, C.; Oikonomou, E.K.; et al. Predictive value of telomere length on outcome following acute myocardial infarction: Evidence for contrasting effects of vascular vs. blood oxidative stress. *Eur. Heart J.* **2017**, *38*, 3094–3104. [CrossRef] [PubMed]

9. Oikonomou, E.K.; Marwan, M.; Desai, M.Y.; Mancio, J.; Alashi, A.; Centeno, E.H.; Thomas, S.; Herdman, L.; Kotanidis, C.P.; Thomas, K.E.; et al. Non-invasive detection of coronary inflammation using computed tomog-raphy and prediction of residual cardiovascular risk (the CRISP CT study): A post-hoc analysis of prospective outcome data. *Lancet* **2018**, *392*, 929–939. [CrossRef] [PubMed]

10. Antonopoulos, A.S.; Sanna, F.; Sabharwal, N.; Thomas, S.; Oikonomou, E.K.; Herdman, L.; Margaritis, M.; Shirodaria, C.; Kompali, A.-M.; Akoumianakis, I.; et al. Detecting human coronary inflammation by imaging perivascular fat. *Sci. Transl. Med.* **2017**, *9*, eaal2658. [CrossRef]

11. Goeller, M.; Achenbach, S.; Cadet, S.; Kwan, A.C.; Commandeur, F.; Slomka, P.J.; Gransar, H.; Albrecht, M.H.; Tamarappoo, B.K.; Berman, D.S.; et al. Pericoronary Adipose Tissue Computed Tomography Attenuation and High-Risk Plaque Characteristics in Acute Coronary Syndrome Compared With Stable Coronary Artery Disease. *JAMA Cardiol.* **2018**, *3*, 858–863. [CrossRef]

12. Hoshino, M.; Yang, S.; Sugiyama, T.; Zhang, J.; Kanaji, Y.; Yamaguchi, M.; Hada, M.; Sumino, Y.; Horie, T.; Nagami, K.; et al. Peri-coronary inflammation is associated with findings on coronary computed tomography angiography and fractional flow reserve. *J. Cardiovasc. Comput. Tomogr.* **2020**, *14*, 483–489. [CrossRef]

13. Yu, M.; Dai, X.; Deng, J.; Lu, Z.; Shen, C.; Zhang, J. Diagnostic performance of perivascular fat attenuation index to predict hemodynamic signif-icance of coronary stenosis: A preliminary coronary computed tomography angiography study. *Eur. Radiol.* **2020**, *30*, 673–681. [CrossRef]

14. Wen, D.; Li, J.; Ren, J.; Zhao, H.; Li, J.; Zheng, M. Pericoronary adipose tissue CT attenuation and volume: Diagnostic performance for hemody-namically significant stenosis in patients with suspected coronary artery disease. *Eur. J. Radiol.* **2021**, *140*, 109740. [CrossRef] [PubMed]

15. Ma, S.; Chen, X.; Ma, Y.; Liu, H.; Zhang, J.; Xu, L.; Wang, Y.; Liu, T.; Wang, K.; Yang, J.; et al. Lesion-Specific Peri-Coronary Fat Attenuation Index Is Associated With Functional Myocardial Ischemia Defined by Abnormal Fractional Flow Reserve. *Front. Cardiovasc. Med.* **2021**, *8*, 755295. [CrossRef] [PubMed]

16. Agatston, A.S.; Janowitz, W.R.; Hildner, F.J.; Zusmer, N.R.; Viamonte, M.; Detrano, R. Quantification of coronary artery calcium using ultrafast computed to-mography. *J. Am. Coll. Cardiol.* **1990**, *15*, 827–832. [CrossRef]

17. Park, H.-B.; Heo, R.; Hartaigh, B.; Cho, I.; Gransar, H.; Nakazato, R.; Leipsic, J.; Mancini, G.B.J.; Koo, B.-K.; Otake, H.; et al. Atherosclerotic plaque characteristics by CT angiography identify coronary lesions that cause ischemia: A direct comparison to fractional flow reserve. *JACC Cardiovasc. Imaging* **2015**, *8*, 1–10. [CrossRef]

18. Pencina, M.J.; D'Agostino, R.B., Sr.; D'Agostino, R.B., Jr.; Vasan, R.S. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. *Stat. Med.* **2008**, *27*, 157–172. [CrossRef] [PubMed]

19. Dunn, O.J. Multiple Comparisons Using Rank Sums. *Technometrics* **1964**, *6*, 241–252. [CrossRef]

20. Libby, P.; Ridker, P.M.; Masera, A. Inflammation and atherosclerosis. *Circulation* **2002**, *105*, 1135–1143. [CrossRef] [PubMed]

21. Ross, R. Atherosclerosis is an inflammatory disease. *N. Engl. J. Med.* **1999**, *340*, 115–126. [CrossRef] [PubMed]

22. Lavi, S.; McConnell, J.P.; Rihal, C.S.; Prasad, A.; Mathew, V.; Lerman, L.O.; Lerman, A. Local production of lipoprotein-associated phospholipase A2 and lysophosphati-dylcholine in the coronary circulation: Association with early coronary atherosclerosis and endothelial dysfunction in humans. *Circulation* **2007**, *115*, 2715–2721. [CrossRef] [PubMed]
28. Ahmadi, N.; Ruiz-García, J.; Hajsadeghi, F.; Azen, S.; Mack, W.; Hodis, H.; Lerman, A. Impaired coronary artery distensibility is an endothelium-dependent process and is associated with vulnerable plaque composition. *Clin. Physiol. Funct. Imaging* **2014**, *36*, 261–268. [CrossRef] [PubMed]

29. Du, Y.; Yang, L.; Liu, Y.; Yang, B.; Lv, S.; Hu, C.; Zhu, Y.; Zhang, H.; Ma, Q.; Wang, Z.; et al. Relation between quantity and quality of peri-coronary epicardial adipose tissue and its underlying hemodynamically significant coronary stenosis. *BMC Cardiovasc. Disord.* **2020**, *20*, 226. [CrossRef]

30. Goeller, M.; Tamarappoo, B.K.; Kwan, A.C.; Cadet, S.; Commandeur, F.; Razipour, A.; Slomka, P.J.; Gransar, H.; Chen, X.; Otaki, Y.; et al. Relationship between changes in pericoronary adipose tissue attenuation and coronary plaque burden quantified from coronary computed tomography angiography. *Eur. Heart J. Cardiovasc. Imaging* **2019**, *20*, 636–643. [CrossRef]

31. Lavi, S.; Yang, E.H.; Prasad, A.; Mathew, V.; Barsness, G.W.; Rihal, C.S.; Lerman, L.O.; Lerman, A. The Interaction Between Coronary Endothelial Dysfunction, Local Oxidative Stress, and Endogenous Nitric Oxide in Humans. *Hypertension* **2008**, *51*, 127–133. [CrossRef]

32. Cereda, A.; Toselli, M.; Palmisano, A.; Vignale, D.; Khokhar, A.; Campo, G.; Bertini, M.; Loffi, M.; Andreini, D.; Pontone, G.; et al. Coronary calcium score as a predictor of outcomes in the hypertensive COVID-19 population: Results from the Italian (S) Core-COVID-19 Registry. *Hypertens. Res.* **2021**, *45*, 333–343. [CrossRef]